Manfred Eigen Campus, Essener Bogen 7
22419 Hamburg, de
+49 (89) 4613363-22
KINAXO launches KinAffinity® services for efficient profiling of kinase inhibitors in cells or tissue
Kinase inhibitors with favorable pharmaceutical properties are extensively pursued as therapeutics in numerous oncological, neurological and inflammatory indications. However, their development faces significant challenges such as target specificity for the disease-relevant target proteins. Here, KinAffinity® provides critical information to select the right lead compound for clinical development.
KinAffinity® combines proprietary chemical proteomics methods with state-of-the-art quantitative mass spectrometry (see Sharma et al., Nature Methods 2009). Endogenously expressed, post-translationally modified kinases are enriched by a ready-to-use affinity matrix in the presence of native binding partners and competed with the kinase inhibitor of interest. Subsequently, bioinformatic methods are used to reveal the inhibitor's quantitative cellular target profile. The inhibitor's targets are ranked by their affinities and reported to the customer.
KinAffinity® is applicable for type I and type II kinase inhibitors. It facilitates selectivity analysis on an organism level that accounts for differences in protein expression between different cells, as well as their mutational and modification status that might affect drug binding.
Meet Kinaxo at Miptec, Basel, October 13-15; at Chi Pipeline Success Summit, Boston, October 13-16 and at Chi Discovery on Target, Boston, November 2-4.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an email@example.com.